Basic Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2019; 11(10): 236-243
Published online Oct 26, 2019. doi: 10.4330/wjc.v11.i10.236
Differential effects of atrial and brain natriuretic peptides on human pulmonary artery: An in vitro study
Azar Hussain, Robert T Bennett, Zaheer Tahir, Emmanuel Isaac, Mubarak A Chaudhry, Syed S Qadri, Mahmoud Loubani, Alyn H Morice
Azar Hussain, Robert T Bennett, Zaheer Tahir, Emmanuel Isaac, Mubarak A Chaudhry, Syed S Qadri, Mahmoud Loubani, Department of Cardiothoracic Surgery, Castle Hill Hospital, Cottingham HU16 5JQ, United Kingdom
Alyn H Morice, Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Castle Hill Hospital, Cottingham HU16 5JQ, United Kingdom
Author contributions: Hussain A was the principal investigator and was responsible for the design and conduct of the study; Hussain A was responsible for the acquisition, analysis and interpretation of the data and initial draft of the manuscript; Bennett RT, Tahir Z, Isaac E, Chaudhry MA, Qadri SS, Loubani M and Morice AH supervised the study and critically reviewed the article.
Institutional review board statement: The study was reviewed and approved by the North West – Liverpool Central Research Ethics Committee (Approval no: 15/NW/0808).
Informed consent statement: All patients were consulted and consented for resected lung tissue to be studied for our research prior to their operation at the time of their consent for surgery.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Azar Hussain, MBBS, MRCS (Ed), Clinical Research Fellow, Department of Cardiothoracic Surgery, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, United Kingdom. azar.hussain@hey.nhs.uk
Telephone: +44-774-8019242
Received: February 10, 2019
Peer-review started: February 12, 2019
First decision: April 11, 2019
Revised: August 31, 2019
Accepted: September 15, 2019
Article in press: September 15, 2019
Published online: October 26, 2019
ARTICLE HIGHLIGHTS
Research background

The prevalence of cardiovascular diseases, especially heart failure, continues to rise worldwide. In heart failure, increasing levels of circulating atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are associated with worsening heart failure and poor prognosis.

Research motivation

ANP and BNP play an important role in homeostasis, but trials with BNP and ANP infusion showed disappointing results for unknown reasons.

Research objectives

The aim of this study was to evaluate whether BNP acts as a partial agonist and inhibits the effect of ANP.

Research methods

In this study, the effect of natriuretic peptides (ANP and BNP) on human pulmonary arteries was evaluated by cumulative addition to the myograph.

Research results

Both ANP and BNP act as pulmonary vasodilators, although ANP was found to be more potent and efficacious than BNP. Also, the addition of BNP reduced the efficacy of ANP.

Research conclusions

The study confirms that BNP inhibits the effects of ANP, and acts as a partial agonist. These findings also explained the disappointing results associated with the ANP and BNP infusion trials.

Research perspectives

Further studies are needed to validate the results of this study, and to evaluate the possibility of the clinical beneficial role of BNP antagonists for heart failure treatment.